Aim: African-Americans (AA) have increased prostate cancer risk and a greater mortality rate than European-Americans (EA). AA exhibit a high prevalence of vitamin D deficiency. We examined the global prostate transcriptome in AA and EA, and the effect of vitamin D 3 supplementation. Patients & methods: Twenty-seven male subjects (ten AA and 17 EA), slated to undergo prostatectomy were enrolled in the study. Fourteen subjects received vitamin D 3 (4000 IU daily) and 13 subjects received placebo for 2 months prior to surgery. Results: AA show higher expression of genes associated with immune response and inflammation. Conclusion: Systems level analyses support the concept that Inflammatory processes may contribute to disease progression in AA. These transcripts can be modulated by a short course of vitamin D 3 supplementation.
There are considerable and persistent racial disparities in prostate cancer outcomes. Prostate cancer disproportionately affects African-American (AA) men in terms of incidence, morbidity, and mortality, even after adjustment for stage. AA men have a two-to three times increased risk of developing prostate cancer and have a greater mortality rate compared with European-American (EA) men. Reduced access to healthcare services contributes to racial disparities in prostate cancer outcomes, but even in equal access healthcare systems such as the Veterans Administration (VA), AA veterans have higher serum prostate-specific antigen (PSA) values and higher-grade tumors than EA veterans even when presenting at the same stage of disease [1, 2] . Thus, access to healthcare is necessary but not sufficient for eliminating racial differences in prostate cancer outcomes. A better understanding of the biological mechanisms underlying these disparities is needed to develop strategies to overcome them.
Exposure of skin to sunlight in the ultraviolet B (UVB) range of the spectrum (290-315 nm) results in the photolytic conversion of 7-dehydrocholesterol to previtamin D 3 , which is transformed to vitamin D 3 (cholecalciferol) by thermally induced isomerization [3, 4] . Vitamin D 3 can be obtained from the diet; however, it is distributed very poorly in natural foodstuffs. Dark skin pigmentation, due to increased melanin levels, likely evolved in equatorial regions to protect individuals from skin cancers. Increased skin pigmentation, however, limits one's ability to produce vitamin D 3 [5, 6] . Vitamin D deficiency occurs when serum levels of 25(OH)D are at <50 nmol (<20 ng/ml); as a result, a majority of AA are vitamin D deficient [6] . Until recently, higher dose vitamin D 3 supplementation was not viewed as a viable treatment modality due to concerns about potential toxicity. However, Vieth et al. [7] examined the efficacy and safety of relatively high intakes of vitamin D 3 by assessing the effects of 1000 and 4000 international units (IU) per day in 61 adults for up to 5 months. They found that vitamin D 3 at a dose of 4000 IU/day was effective in elevating the serum 25(OH)D concentration to values ≥40 ng/ml of serum. Our own clinical experience with prolonged supplementation with 4000 IU/day for 12 months has demonstrated the safety of this regimen. We have observed that 4000 IU/day are extremely effective at raising circulating 25(OH)D across racial groups [8, 9] , to levels measured in athletes during summer training [10] .
Prostate cells express the vitamin D receptor (VDR), vitamin D-25-hydroxylase, 25-hydroxyvitamin D-1-alpha-hydroxylase and the 25-hydroxyvitamin D-24-hydroxylase [11] [12] [13] [14] [15] [16] [17, 18] . 1,25(OH) 2 D 3 is the hormonal, most potent form of vitamin D and in prostate cells it acts in a paracrine/autocrine fashion.
Several mechanisms of vitamin Dmediated anticancer action have been identified [19] . Vitamin D suppresses the expression of cyclo-oxygenase-II, the key enzyme for the synthesis of prostaglandins, mediators of inflammation and thought to be important for cancer progression [20] ; cyclo-oxygenase-II expression in biopsy cores and prostate cancer surgical specimen is an independent predictor of recurrence [21] . Furthermore, there is considerable evidence that calcitriol inhibits nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling, and decreases the levels of the angiogenic and pro-inflammatory cytokine IL-8 in prostate cancer cells [22] . NFκB is a transcription factor that plays a central role in the control of inflammation and is expressed at high levels in prostate cancers with high Gleason scores [23] . This is only a very limited list of the many molecular pathways and mechanisms affected by vitamin D, as it is now well established that VDR may recognize cognate VDRE present within the regulatory sequences of hundreds of human genes, implicating vitamin D in a vast network of gene regulation, and underlying its broad physiological actions [24, 25] . While it is well established that vitamin D and calcium are crucial for normal skeletal growth and for maintenance of the mechanical and structural integrity of the skeleton [26] , the recent emphasis on nonskeletal functions of vitamin D has to do with the realization that vitamin D deficiency has major implications for human health in general, and cancer biology in particular [9] .
Racial disparities in prostate cancer outcomes mirror racial differences in circulating levels of vitamin D [27] .
Furthermore, about 60% of AA men have suboptimal levels of circulating 25(OH)D 3 [28, 29] . For this reason, vitamin D 3 supplementation is likely to benefit these men. Vitamin D supplementation has no effect on free or total prostate-specific antigen (PSA) in AA men [30] . The effects of 25-OHD levels on the risk of total, lowand high-grade prostate cancer were examined in two separate studies, the SELECT [31] and the PCPT [32] . In the former, plasma 25-OHD levels were associated with a linear decrease in prostate cancer risk for high-grade cancers in AA men and an apparent 'U'-shaped effect in other men reflecting detection bias. In the latter, which minimized detection bias, serum 25-OHD levels were associated with a linear decrease in the risk of highgrade prostate cancers. These data support the hypothesis that circulating levels of 25-OHD decrease the risk of clinically relevant prostate cancers and emphasize the need to further assess the influence of vitamin D supplementation on prostate cancer prevention Vitamin D promotes the differentiation of prostate cancer cells and maintains the differentiated phenotype of prostate epithelial cells, raising the possibility that long-term vitamin D deficiency may contribute to the progression from subclinical prostate cancer to clinical disease, especially among AA men [27] . Therefore, eliminating racial disparities in circulating levels of vitamin D could help reduce disparities in prostate cancer outcomes.
We completed an open-label clinical trial aimed at assessing the safety and potential efficacy of vitamin D 3 supplementation at 4000 IU per day for one year in patients diagnosed with low-risk prostate cancer [33] . The combination of active surveillance and vitamin D 3 supplementation resulted in a decreased number of positive cores at repeat biopsy in half of subjects enrolled in this trial, and a comparison between supplemented subjects and historical controls suggested that supplementation with vitamin D 3 at 4000 IU per day may benefit patients with low-risk prostate cancer on active surveillance [33] .
These observations prompted us to initiate a prospective clinical study aimed at examining the effects of vitamin D 3 supplementation at 4000 IU per day for 2 months in male subjects who selected surgical removal of the prostate (prostatectomy) as a definitive treatment for their prostate cancer. According to current standard of care, a 2-month interval between biopsy and prostatectomy is recommended to resolve the inflammation due to the biopsy procedure. Moreover, we reported that the initial 2 months of vitamin D 3 supplementation register the fastest raise in serum levels of 25(OH)D 3 [8, 9] .
The primary goal of this study was to examine molecular differences in gene expression patterns rel-evant to prostate cancer disparities between AA and EA men, and investigate the global effects of vitamin D 3 supplementation on the prostate transcriptome. To further this objective, we undertook a series of genome wide expression profiling experiments using high-throughput (HT) RNA sequencing. RNA was purified from prostate tissue specimens obtained at surgery from subjects enrolled in the study. Transcriptional profiles of each of the patient's tissue samples were generated and systems level analyses were performed.
Patients & methods

Human subjects
This human study was approved by the Institutional Review Board (IRB) of the Medical University of South Carolina (MUSC; SC, USA), and the Ralph H Johnson VA Medical Center (VAMC; SC, USA) and by the Research and Development (R&D) Committee of the VAMC. This interventional study was performed under investigational new drug (IND) 77839, granted to SGC by the US FDA. Male subjects enrolled in this study were diagnosed with localized prostate cancer. The study enrolled 27 subjects (ten AA and 17 EA men), who had selected surgical removal of the prostate (prostatectomy) as a definitive treatment for their prostate cancer. According to current standard of care, a 2-month interval between biopsy and prostatectomy is recommended to resolve the inflammation due to the biopsy procedure. Enrolled subjects were randomized to vitamin D 3 (Carlson Laboratories, IL, USA) supplementation at 4000 IU per day or placebo for 2 months prior to surgery. Two blood samples were obtained from each subject (at enrollment and on the day of surgery) to measure serum levels of 25-hydroxyvitamin D 3 (25[OH]D 3 ) in nanograms (ng) per milliliter (ml). In total 14 subjects (five AA and nine EA men) took 4000 IU of vitamin D3 per day for 2 months prior to surgery; 13 subjects (five AA and eight EA men) received placebo for 2 months prior to surgery. Based on the serum levels of 25(OH)D at study exit, we concluded that there was a high level of compliance by all enrolled subjects.
Tissue sample procurement & RNA purification
Surgical specimens were received in the frozen section laboratory of the MUSC or the VAMC, depending on where the prostatectomy was performed. Nonmalignant tissue samples were excised from the peripheral zone of the prostate under the supervision of the attending pathologist, to ensure that the excision of tissue samples did not interfere with the diagnostic priorities of standard of care. Specifically, the attending pathologist identified for us nonmalignant tissue away from cancer lesions, based on his knowledge of the location, within the prostate, of cancer-positive biopsy cores prior to surgery. Tissue samples were transferred to sterile tubes, quick-frozen in liquid nitrogen and transported to the Hollings Cancer Center Genomics Core Facility (SC, USA). Total RNA from each de-identified tissue sample was purified on a Qiagen RNeasy column (Qiagen, CA, USA) according to manufacturer's instructions. RNA integrity was verified using RNA 6000 Nano Assay chips run in Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA).
RNA sequencing (RNA-seq) & analyses
Around 100-200 ng of total RNA was used to prepare RNA-Seq libraries using the TruSeq RNA Sample Prep Kit (Illumina, CA, USA), following the protocol described by the manufacturer. High-throughput sequencing (HTS) was performed using an Illumina HiSeq2500 with each sample sequenced to a minimum depth of ∼50 million reads. Data were subjected to Illumina quality control (QC) procedures (>80% of the data yielded a Phred score of 30). Secondary analysis was carried out on an OnRamp Bioinformatics Genomics Research Platform (OnRamp Bioinformatics, CA, USA). OnRamp's advanced Genomics Analysis Engine utilized an automated RNAseq workflow to process the data, including data validation and quality control, read alignment to the human genome (hg19) using TopHat2 [34] , which revealed >93% mapping of the paired end reads, generation of gene-level count data with HTSeq and differential expression analysis with DEseq2 [35] , which enabled the inference of differential signals with robust statistical power. The resulting SAM files were sorted and inputted into the Python package HTSeq to generate count data for gene-level differential expression analyses. In order to infer differential signal within the datasets with robust statistical power, we utilized DEseq2 [35] . Transcript count data from DESeq2 analysis of the samples were sorted according to their adjusted p-value or q-value, which is the smallest false discovery rate (FDR) at which a transcript is called significant. FDR adjustment is needed with large datasets such as RNAseq. FDR is the expected fraction of false-positive tests among significant tests and was calculated using the Benjamini-Hochberg multiple testing adjustment procedure. Statistical analysis of pathways and gene ontology (GO) terms was carried out using this sorted transcript list as described by us previously [36, 37] and using Ingenuity Pathway Analysis (Qiagen) and the Topp-The study enrolled 27 subjects (ten AA and 17 EA men), who had selected surgical removal of the prostate (prostatectomy) as a definitive treatment for their prostate cancer. Table 1 highlights the characteristics of enrolled subjects, their age and race distribution, disease stage and serum levels of 25(OH)D 3 . Baseline and exit values of serum levels of 25(OH)D 3 are shown in ng/ml. Baseline Gleason grade refers to the pathology assessment of the prostate biopsy at diag nosis. Exit Gleason grade refers to the pathology assessment on the entire prostate after surgery, which may have resulted in upgrade, downgrade or no change of the pathology assessment. Overall, there was no significant change in pathology assessment on the prostate after surgery, compared with the previous biopsy, either by race or by supplementation. All 14 subjects receiving vitamin D 3 supplementation had an increase in their serum concentration of 25(OH)D 3 . There were no significant changes in circulating levels of vitamin D in the 13 subjects receiving placebo. Differences in serum concentration of 25(OH)D 3 measured at study entry between AA and EA subjects were erased after 2 months of supplementation 
Differential prostate gene expression between AA and EA patients
We set EA subjects (17 samples) as the control and AA subjects (ten samples) as the test to uncover genes differentially expressed in AA. These cumulative patient datasets were analyzed to identify race-associated differences in prostate gene expression between samples from AA and EA subjects, as well as differences in molecular changes in the prostate associated with vitamin D 3 supplementation. Fold-change (FC) estimation and hypothesis testing for differential expression were performed using the DESeq2 Bioconducter library [35, 40, 41] . For each gene, DESeq2 reported an estimated FC, and provided an adjusted p-or q-value equivalent to the smallest FDR incurred when declaring that test significant.
When we assessed differences in prostate gene expression between AA subjects (ten samples) compared with EA subjects (17 samples), this revealed that 3107 genes were differentially expressed between the two groups (q < 0.1). Pathway and GO analysis using (QIAGEN Ingenuity Pathway Analysis) with the 3107 differentially expressed genes uncovered major differences between the two groups Table 2; Supplementary Table 3) . Examples of these canonical pathways include, 'regulation of immune response', 'lymphocyte activation and T-cell activation' (Figure 2 ) and 'dendritic cell maturation', 'complement system', 'crosstalk between dendritic cells and natural killer cells' and 'NF-κB signaling' (Figure 3 ).
Differential prostate gene expression between AA supplemented with vitamin D 3 
or placebo
We subsequently identified differentially expressed genes in prostate tissue specimens from five AA subjects supplemented with vitamin D 3 at 4000 IU/day for 2 months compared with five AA subjects receiving placebo. 817 transcripts were significantly differentially expressed between these two groups (q < 0.4). GO analysis using the 817 differentially expressed genes revealed chemo kine activity, chemo kine receptor binding and G-protein coupled receptor binding as significantly enriched terms (Table 3, Supplementary Table 4) . Pathway analysis indicated that transcripts belonging to the 'calcium signaling' (BioSystems: KEGG, 1.26E -05 ), and 'chemo kine receptors bind chemokines' (BioSystems: REACTOME, 1.53E -02 ) pathways were significant in the vitamin D 3 or placebo comparison. It must be noted that vitamin D 3 supplementation in EA patients had no significant effect on gene expression (of the 17 samples examined, nine were supplemented with vitamin D 3 and eight received placebo). We examined the lists of transcripts regulated by vitamin D 3 for overlap with those that were differentially expressed between AA and EA (Figure 4) . Among those that overlapped were unc-5 netrin receptor C (UNC5C), fibroblast growth factor 10 (FGF10), a junctional protein associated with coronary artery disease (KIAA1462), ADAM-like decysin 1, (ADAM-DEC1), vitrin (VIT ), tachykinin receptor 2 (TACR2), FRMD6 antisense RNA 2 (FRMD6-AS2), adaptor related protein complex 1 sigma 3 subunit (AP1S3), pleckstrin homology domain containing N1 (PLE-KHN1), coiled-coil domain containing 27 (CCDC27), FGF10 antisense RNA 1 (FGF10-AS1), myosin, heavy chain 6, cardiac muscle, alpha (MYH6 ), cingulinlike 1 (CGNL1), ventricular zone expressed PH domain containing 1 (VEPH1) and collagen, type IV, alpha 3 (COL4A3) (q < 0.1) in both comparisons. Furthermore, comparison of the 8238 transcripts that were differentially expressed between AA and EA subjects (q < 0.4) and the 817 genes that were differentially expressed in AA subjects supplemented with vitamin D 3 compared with AA subjects receiving placebo (q < 0.4) revealed an overlap of 346 genes (Figure 4 ). This overlap suggested that a considerable number of genes that are differentially expressed between across racial groups, can be affected by a very short course of vitamin D 3 supplementation in AA subjects.
GO and pathway analysis of these 346 genes using Toppfun revealed enriched terms generally related to development and differentiation (Supplementary Table 1) . Co-expression analysis with this list of 346 revealed a signature related to 'M19391; genes downregulated in prostate cancer samples', MSigDB C2: Broad Institute (2.121E -9 ). GO and pathway analysis of the 471 genes that did not overlap revealed primarily immune signatures including 'CXCR chemokine receptor binding', 'cytoskeletal protein binding', 'chemokine activity' and ' chemokine receptor binding' (Supplementary Table 2) .
Comparison of transcripts differentially expressed between AA & EA in patients who were treated with placebo versus those treated with vitamin D 3 . Twenty-seven subjects completed the study. Age, race and randomization assignment for each enrolled subject are shown. Baseline and exit values of serum levels of 25(OH)D3 are shown in ng/ml. Baseline Gleason grade refers to the pathology assessment of the prostate biopsy preceding the surgery. Exit Gleason grade refers to the pathology assessment on the entire prostate after surgery, which may result in upgrade, downgrade or no change of the pathology assessment. Analysis of the 3107 differentially expressed genes (q < 0.1) using Ingenuity Pathway Analysis (QIAGEN, CA, USA) uncovered altered immune system and inflammatory signatures between these two groups. Significant enriched canonical pathways are displayed along the y-axis. The x-axis (top) displays the -log of the p-value (calculated by Fisher's exact test right-tailed and adjusted for false discovery rate using Benjamini-Hochberg. Taller bars correspond to increased pathway significance. Orange colored bars indicate pathway activation in African-American relative to European-American. White bars indicate significant pathways in African-American compared with European-American that are neither activated nor inhibited. Gray bars indicate pathways that are significant but no prediction as to their activation or inhibition can be made. The orange points connected by a thin line represent the ratio (x-axis bottom). The ratio is calculated as follows: the number of genes in a particular pathway that are significantly enriched in the RNA-seq dataset are divided by the total number of genes that make up that pathway and are present in the reference gene set.
future science group GDF15 is one example of a vitamin D sensitive gene 'captured' by our research approach. Low expression of GDF15 is associated with prostate cancer progression [42, 43] . We examined the expression pattern of GDF15 mRNA in our RNAseq datasets ( Figure 5 ). GDF15 expression was significantly downregulated in from AA subjects compared with EA subjects (q = 0.16). In AA subjects receiving vitamin D 3 supplementation, GDF15 mRNA expression was significantly upregulated relative to those receiving placebo (q = 0.09). In EA subjects receiving vitamin D 3 supplementation, GDF15 mRNA expression was upregulated (although this was not statistically significant, q = 0.99) relative to those receiving placebo.
Discussion
The objective of this clinical study was to investigate the molecular effects of vitamin D 3 supplementation (4000 IU per day for 2 months) on prostate tissue specimens obtained at surgery, by means of HT RNA- Table 2 . GO analysis of differences in prostate gene expression between African-American subjects and European-American subjects. 
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The top 5 GO terms are presented. A more detailed analysis is presented in Supplementary Table 3 .
Regulation of immune response
Lymphocyte activation EA  AA  EA  AA  EA  AA   FFAR3  IL1B  ICAM1  BCL2A1  FCN1  FCGR1A  FCGR2A  SAMSN1  C5AR1  CTLA4  ITK  CCR1  SELL  LILRB2  FCGR2B  CD79A  FCRL5  IRF4  CD40LG  TRAT1  SH2D1A  CD28  LAX1  ZBP1  CD3G  GPX2  NOD2  PTPN22  THEMIS2  AMICA1  ITGA4  CD1D  TLR6  BTK  CD200R1  FCER1A  THEMIS  RASGRP1  GFI1  SLA2  CD8A  TLR1  HLA-DMB  ITGB7  SKAP1  CD79B  CD37  SASH3  PTPRC  FYB  ITGAL  CD3E  CD96  CD3D  KLRB1  CR1  VSIG4  C3AR1  TLR8  CCR2  MNDA  TNFSF13B  LILRA1  CD14  ITGB2  CD4  HLA-DRA  CD74  C1QC  C1QA  C1QB  HCST  CTSS  LILRB1  HCK  CD300A  ITGAM  TYROBP  MYO1F  CD86  FCER1G  LY96  CD226  TNFAIP3  TLR2  LCP2  ADA  PLSCR1  VCAM1  FOXF1  FGF10  RFTN1  C1S  SERPING1  FGF7  FGFR4  C7  PLCL2  CMTM3  PDGFRA  IL6ST  IL33  WIPF1  PDGFRB  FYN  SAMHD1  ELMO1  NLRC4  CLEC7A  PIK3AP1  PROS1  PDE4B  NCKAP1L  NR1D1  PELI2  DDX58  JAK1  STAT5B  ACTR3  ACTR2  PAK2  ADAR  SIN3A  MAPK1  MEF2A  PAK1  PTEN  ICAM3  HSP90AA1  FCN2  MALT1  DHX58  PLA2G6  PRKD2  SAC3D1  FADD  MLST8  HRAS  STK11  SPPL2B  RBCK1  MAP2K7  RAC1  RPS27A  IKBKG  EXOSC6  FGF5  BAIAP2  HLA-C  HLA-H  KLRD1  UBE2V1  MOG  HLA-G   CD79A  LAX1  CD3G  CD28  MZB1  SLAMF7  IRF4  SLAMF1  ICOS  CD40LG  VNN1  ICAM1  IL1B  BCL2A1  ITGAX  LILRB2  FCGR2B  CD180  CD1C  CTLA4  GPR183  CXCR4  CD5  ITK  PDCD1  TNFSF8  SAMSN1  RHOH  TNFAIP3  STX11  PRDM1  VCAM1  IL18R1  IL6ST  FYN  ADA  PDCD1LG2  EBI3  FGF10  CXCR5  BTK  CD1D  CD300A  CORO1A  SASH3  IL2RG  AMICA1  PTPRC  IKZF1  DOCK2  ITGA4  CD86  CD4  HLA-DRA  CD74  ITGAM  LST1  SPI1  AIF1  ITGB2  MNDA  CCR2  LILRB1  CD48  SIT1  KLRB1  PIK3CG  ITGAL  CD3E  CD2  CD3D  TIGIT  FLT3  VSIG4  CLEC7A  TNFSF13B  GAPT  EOMES  BCL11B  PTPN22  NOD2  NCKAP1L  CD83  ZBTB32  CD27  SLA2  CD8A  HLA-DOA  HLA-DMB  THEMIS  PRLR  IGF1  PLCL2  FZD7  CXCL12  PREX1  PAK1  NEDD4  NBN  RNF168  PAK2  TP53  MSH6  STAT5B  CTNNB1  GON4L  PRKDC  HSP90AA1  EXOSC6  MICA  NCK2  STK11  RAC1  DHPS  POLM  FADD  MLST8  RHBDD3  MALT1  ZBTB16  IHH  FOXN1  HLA-G   VNN1   CTLA4   CD1C   LILRB2   ITGAX   BCL2A1   ICAM1   IL1B   ICOS   IRF4 A major objective of this study was to investigate the molecular mechanisms relevant to prostate cancer disparities between AA and EA men, and explore the potentially beneficial effects of vitamin D 3 supplementation on the prostate in AA men. We noted that the global transcriptomes of AA and EA men were considerably different. Our observations of increased inflammatory and immune signatures are consistent with a previous report by Wallace and colleagues (Supplementary Figures 2 & 3 ) [44] . The goal of this earlier study was to apply Affymetrix array based genomewide gene expression profiling of prostate tumors to determine differences in tumor biology between 33 AA and 36 EA patients. Their analysis uncovered 162 significant genes (q < 0.05) that were differently expressed between AA and EA patients. Using a disease association-based approach analysis, a common theme among these transcripts was autoimmunity and inflammation, including 'immune response', 'stress response', 'cytokine signaling' and 'chemotaxis' pathways. The authors showed that metastasis-promoting genes, including autocrine mobility factor receptor, chemokine (C-X-C motif) receptor 4 (CXCR4) and matrix metalloproteinase 9 (MMP-9), were expressed at higher levels in AA relative to EA, highlighting the existence of a distinct tumor microenvironment in these two patient groups. The results of our transcriptomic analyses using a newer technology (RNA-seq) applied to prostate tissue samples acquired prospectively as part of a randomized, interventional clinical study further support the existence of considerable biological differences within the prostate between AA and EA men, and suggest that overexpression of genes linked to inflammatory processes likely contribute to the increased severity and faster progression of prostate cancer in AA even at the early stage of disease. Using IPA canonical pathway analyses, we noted activation of 'FCγ receptor mediated phagocytosis in macrophages and mononcytes', 'TREM1 signaling', 'role of NFAT in the regulation of the immune response', 'iCOSiCOSL signaling in T helper cells', 'NF-κB signaling and leukocyte-extravasation signaling' (Figure 1) in AA subjects, all of which highlight differences in immune and inflammatory response. A general trend we observed with GO and pathway analyses were upregulation of transcripts in AA compared with EA, that were relevant to the immune system: segulation of immune response, lymphocyte activation and T-cell activation (Figure 2 ) and dendritic cell maturation and complement system activation ( Figure 3) .
T-cell activation
We also identified differentially expressed genes in prostate tissue specimens from five AA subjects supplemented with vitamin D 3 at 4000 IU/day for 2 months compared with five AA subjects receiving placebo. Expression of 124 genes was significantly different between these two groups with a stringent FDR <0.1 cut-off, while expression of 817 genes was significantly different between these two groups at a less stringent FDR <0. We released the FDR stringency to explore overlap between the differentially expressed transcripts in prostate tissue specimens from AA subjects compared with EA subjects, i.e., 8237 unique transcripts (FDR <0.4), and differentially expressed genes in prostate tissue specimens from AA subjects supplemented with vitamin D3 compared with AA subjects receiving placebo, i.e., 817 unique transcripts (FDR <0.4). This analysis revealed an overlap of 346 genes (Figure 3 ) and suggested that a considerable number of genes that are differentially expressed between AA and EA subjects, can also be affected by a very short course of vitamin D 3 supplementation. Of note, when we performed coexpression analysis with this short gene list, we uncovered a signature corresponding to genes downregulated in prostate cancer samples, further indicating that at a molecular level, vitamin D has potentially beneficial effects. Furthermore, vitamin D 3 supplementation in EA patients had no significant effect on gene expres- CD40LG   IL1B   NGF   TLR8   TNFSF13B   TLR1   PIK3CG   TLR6   PIK3R5   FCER1G   TNFRSF1B   TNFAIP3   TLR2   TGFBR1   FGFR4   PDGFRA   TGFBR3   IL33   PDGFRB   BMPR2   TANK sion (of the 17 samples examined, nine were supplemented with vitamin D 3 and eight received placebo), consistent with the concept that even a short course of supplementation will especially impact transcription in the prostate of AA men, possibly because of their pronounced vitamin D deficiency. GDF15 is a protein belonging to the TGF-β superfamily. It functions in regulating inflammatory and apoptotic pathways in injured tissues and during disease processes [42] . We examined the expression pattern of GDF15 mRNA in our RNAseq datasets ( Figure 5 ). GDF-15 is highly expressed in the prostate and has been associated with inflammation and tumorigenesis. In a recent study of prostatic inflammation, GDF-15 expression was determined via immunohistochemical staining of human prostatectomy specimens containing inflammation. Expression in luminal epithelial cells was found to be reduced with increasing inflammation severity, suggesting an inverse association between GDF-15 and inflammation [43] . Overlap between differentially expressed transcripts in prostate tissue specimens from AA subjects compared with EA subjects (8237 unique transcripts), and differentially expressed genes in prostate tissue specimens from AA subjects supplemented with vitamin D3 at 4000 IU per day for 2 months compared with AA subjects receiving placebo (817 unique transcripts). AA: African-American; EA: European-American. Figure 5 . Analysis of the expression patterns of GDF15 mRNA. GDF15 mRNA expression was significantly downregulated investigated in from AA subjects compared with EA subjects. In AA subjects receiving vitamin D3 supplementation, GDF15 mRNA expression was significantly upregulated relative to those receiving Pl. In EA subjects receiving vitamin D3 supplementation, GDF15 mRNA expression was upregulated (although not significantly) relative to those receiving placebo. AA: African-American; EA: European-American: PI: Placebo; VitD: Vitamin D. In our patient cohort we observed that GDF-15 was down regulated in AA compared with EA (-1.65 fold and highly significant at an FDR = 0.16), suggesting increased prostatic inflammation in AA ( Figure 5 ). Vitamin D 3 supplementation in AA subjects resulted in upregulated GDF-15 expression, (2.45-fold in tissue samples from supplemented subjects relative to subjects receiving placebo, and highly significant at an FDR = 0.091). Based on the previously reported inverse association between GDF-15 and inflammation, a reduction in inflammatory processes would be expected in supplemented subjects. As accumulating evidence suggests that chronic prostatic inflammation may lead to prostate cancer development, vitamin D 3 supplementation in AA is likely beneficial [43] . In supple mented EA subjects, we observed an upregulation of GDF-15 (1.28-fold but not statistically significant) compared with EA subjects receiving placebo.
NF-κB signaling
It has recently been reported that in vitamin D deficient men initial biopsies are more likely to show prostate tumors with high Gleason grade and more advanced clinical stage than biopsies from men who are not vitamin D deficient [45] . Furthermore, this association was particularly strong for AA men who were vitamin D deficient [45] [46] , the main objective of our research effort is to fill existing gaps in knowledge by identifying those mechanisms and pathways that are especially relevant to understand the effects of vitamin D on the prostate, as well as on prostate cancer disparities between AA and EA men. These data are needed to inform treatment recommendations for vitamin D 3 supplementation and provide prescription guidelines to be used in the clinical setting as a treatment strategy for early-stage prostate cancer.
Finally we examined the expression patterns of vitamin D associated genes CYP27A1, GC (groupspecific component [vitamin D binding protein]), CYP3A4, CYP2R1, DHCR7, NADSYN1, CYP27B1 and CYP24A1. We interrogated our datasets for any differences in expression patterns of these transcripts between supplemented and placebo-receiving AA subjects but noted that they were not differentially expressed. This result is not surprising because we have consistently observed that vitamin D 3 supplementation normalizes all the vitamin D related bio chemical parameters that we have measured in AA compared with EA. If there were physiologically relevant genetic differences mapped through single nucleotide variations associated with these genes, we would have expected transcriptomic differences.
Conclusion
This report represents an important first step in our effort to elucidate the molecular underpinnings of health disparities in prostate cancer. The results of our RNA-seq analyses highlight significant differences in the transcription profiles in prostate tissue samples between AA and EA men. Additional differences were observed between subjects supplemented with vitamin D 3 and subjects receiving placebo, suggesting that even a short period of vitamin D 3 supplementation can have a significant impact on prostate gene expression. In view of the widespread vitamin D deficiency among AA men and their increased risk of developing prostate cancer, a deeper understanding of race-based transcriptomic differences and vitamin D driven pathways in prostate tissue will allow us to better justify vitamin D 3 supplementation as a therapeutic option for early-stage prostate cancer, especially in AA men.
We acknowledge that the sample size is a limitation of this study. Therefore, in future studies we plan to enlarge the enrollment of eligible subjects by expanding the scope of RNA-seq analyses to single-core prostate biopsy samples obtained prospectively. The results of the RNA-seq analyses reported here were obtained with tissue samples of <50 mg, equivalent to the weight of a single-core biopsy. These additional subjects will also be stratified according to race, serum levels of vitamin D, serum levels of PSA, Gleason score, and supplementation. These future clinical studies will allow us to validate the concept that the prostate appears to be, at the molecular level, a 'sentinel' organ for health disparities.
Executive Summary
• Prostate cancer disproportionately affects African-American (AA) men in terms of incidence, morbidity and mortality, even after adjusting for stage.
• Racial disparities in prostate cancer outcomes mirror racial differences in circulating levels of vitamin D. AA men exhibit a high prevalence of vitamin D deficiency.
• The first goal of this study was to determine whether there are significant differences in the transcription profile of prostate tissue specimens between AA and European-American (EA) men.
• The second goal of this study was to determine whether vitamin D 3 supplementation could affect these differences.
• Twenty-seven subjects (ten AA and 17 EA men), slated to undergo prostatectomy, were enrolled in the study.
• Fourteen of these subjects received vitamin D 3 supplementation (4000 IU/day) and 13 subjects received placebo for 2 months before surgery.
• RNA was purified from prostate tissue specimens obtained at surgery and RNA-seq analyses were performed on all samples. • A total of 3107 genes were differentially expressed (FDR <0.1). Pathway and GO analysis indicated that AA show higher expression of genes associated with immune response and inflammation. • A total of 817 genes were differentially expressed in AA subjects supplemented with vitamin D 3 compared with those receiving placebo.
• These results support the existence of fundamental biological differences within the prostate between AA and EA men and suggest that overexpression of genes linked to the inflammatory process may contribute to the increased severity and faster progression of prostate cancer in AA men.
• These findings also suggest that a considerable number of genes that are differentially expressed in AA compared with EA subjects, can be affected by a short course of vitamin D 3 supplementation.
• The prostate appears to be, at the molecular level, a 'sentinel' organ for health disparities.
